Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.40 |
| ▸ | PGR | P06401 | 1/20 | 0.39 |
| ▸ | ADORA1 | P30542 | 4/20 | 0.39 |
| ▸ | ADORA2A | P29274 | 4/20 | 0.39 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | RORB | Q92753 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.36 |
| ▸ | EIF4E | P06730 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8301477 | 0.92 | PTGDR2 (0.44) | PTGDR2ADORA1ADORA2AADORA2BEIF4E | |
| SCHEMBL8322492 | 0.89 | GRM5 (0.36) | — | |
| SCHEMBL8236352 | 0.88 | XDH (0.44) | PTGDR2ADORA1ADORA2AADORA2BTDP1 | |
| SCHEMBL8236048 | 0.88 | XDH (0.44) | PTGDR2ADORA1ADORA2AADORA2BTDP1 | |
| SCHEMBL12942047 | 0.88 | RORB (0.41) | RORBKMT2AMAPK14 | |
| SCHEMBL8304829 | 0.85 | PTGDR2 (0.38) | PTGDR2PGRADORA1ADORA2AADORA2B | |
| SCHEMBL8292580 | 0.84 | PTGDR2 (0.45) | PTGDR2 | |
| SCHEMBL8294962 | 0.82 | PTGDR2 (0.43) | PTGDR2ADORA1ADORA2AADORA2BRORB | |
| SCHEMBL8285414 | 0.82 | PTGDR2 (0.43) | PTGDR2ADORA1ADORA2AADORA2BRORB | |
| SCHEMBL8235754 | 0.82 | RORB (0.47) | ADORA1ADORA2ARORBKMT2AMAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2467381-B1 | SUBSTITUTED (THIAZOLYL-CARBONYL)IMIDAZOLIDINONES AND THIER USE FOR THE TREATMENT OF RETROVIRAL DISEASES | AICURIS GMBH & CO KG (DE) | 2014-04-30 | — | — | EP | disclosed |
| EP-2467381-B1 | SUBSTITUTED (THIAZOLYL-CARBONYL)IMIDAZOLIDINONES AND THIER USE FOR THE TREATMENT OF RETROVIRAL DISEASES | AICURIS GMBH & CO KG (DE) | 2014-04-30 | — | — | EP | disclosed |
| US-8575357-B2 | Substituted (thiazolyl-carbonyl)imidazolidinones and use thereof | AICURIS GMBH & CO. KG (DE) | 2013-11-05 | — | — | US | disclosed |
| US-8575357-B2 | Substituted (thiazolyl-carbonyl)imidazolidinones and use thereof | AICURIS GMBH & CO. KG (DE) | 2013-11-05 | — | — | US | disclosed |
| US-8575357-B2 | Substituted (thiazolyl-carbonyl)imidazolidinones and use thereof | AICURIS GMBH & CO. KG (DE) | 2013-11-05 | — | — | US | disclosed |
| US-20130045999-A1 | SUBSTITUTED (THIAZOLYL-CARBONYL)IMIDAZOLIDINONES AND USE THEREOF | AICURIS GMBH & CO. KG (DE) | 2013-02-21 | — | — | US | disclosed |
| US-20130045999-A1 | SUBSTITUTED (THIAZOLYL-CARBONYL)IMIDAZOLIDINONES AND USE THEREOF | AICURIS GMBH & CO. KG (DE) | 2013-02-21 | — | — | US | disclosed |
| US-20130045999-A1 | SUBSTITUTED (THIAZOLYL-CARBONYL)IMIDAZOLIDINONES AND USE THEREOF | AICURIS GMBH & CO. KG (DE) | 2013-02-21 | — | — | US | disclosed |
| EP-2467381-A1 | SUBSTITUTED (THIAZOLYL-CARBONYL)IMIDAZOLIDINONES AND USE THEREOF FOR TREATING RETROVIRAL DISEASES | AiCuris GmbH & Co. KG (DE) | 2012-06-27 | — | — | EP | disclosed |
| WO-2011020822-A1 | SUBSTITUTED (THIAZOLYL-CARBONYL)IMIDAZOLIDINONES AND USE THEREOF FOR TREATING RETROVIRAL DISEASES | AICURIS GMBH & CO. KG (DE) | 2011-02-24 | — | — | WO | disclosed |
| WO-2011020822-A1 | SUBSTITUTED (THIAZOLYL-CARBONYL)IMIDAZOLIDINONES AND USE THEREOF FOR TREATING RETROVIRAL DISEASES | AICURIS GMBH & CO. KG (DE) | 2011-02-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130045999-A1 | SUBSTITUTED (THIAZOLYL-CARBONYL)IMIDAZOLIDINONES AND USE THEREOF | TPMT, AADAC, PAICS | PTGDR2 2267/4885PGR 3388/4885ADORA1 3895/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.